Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Total Liabilities (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Total Liabilities for 4 consecutive years, with $64.8 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 66.24% to $64.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $64.8 million through Dec 2025, down 66.24% year-over-year, with the annual reading at $64.8 million for FY2025, 66.24% down from the prior year.
  • Total Liabilities for Q4 2025 was $64.8 million at Century Therapeutics, down from $68.4 million in the prior quarter.
  • The five-year high for Total Liabilities was $194.3 million in Q2 2024, with the low at $64.8 million in Q4 2025.
  • Average Total Liabilities over 4 years is $152.5 million, with a median of $175.3 million recorded in 2022.
  • The sharpest move saw Total Liabilities increased 14.6% in 2024, then plummeted 66.24% in 2025.
  • Over 4 years, Total Liabilities stood at $183.8 million in 2022, then dropped by 4.28% to $175.9 million in 2023, then grew by 9.04% to $191.9 million in 2024, then tumbled by 66.24% to $64.8 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $64.8 million, $68.4 million, and $74.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.